Key facts
- Tulavi Therapeutics’s last known valuation is $83.0M (Jul 2025).
- It has raised $34.0M across 4 recorded rounds; the latest was Seed Round ($1.0M) in Dec 2021.
- Notable investors include Ascension Ventures, AMED Ventures, Delos Capital Partners, Incept, Iyengar Capital — 6 tracked in total.
- Tulavi Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently Dec 2021 ($1.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Tulavi Therapeutics
Funding rounds
4 roundsAbout Tulavi Therapeutics
Developer of a medical technology platform designed to improve nerve repair and support recovery after nerve injury. The company offers intuitive nerve repair technologies, enabling surgeons and healthcare providers to treat nerve damage more consistently and support better patient outcomes.
- Sector
- Healthcare
- HQ
- Los Gatos, CA, United States
- Founded
- 2018
- Employees
- 31
- Website
- tulavi.com/
- Ownership
- Privately Held (backing)
Tulavi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tulavi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tulavi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.